Annovis Bio (ANVS) Corporate presentation summary

Clinical development and pipeline

• Lead asset buntanetap targets both Alzheimer's and Parkinson's diseases, with late-stage clinical trials completed or ongoing for both indications.

• Pivotal Phase 3 trial in early Alzheimer's is ongoing, with enrollment nearly complete at 80 U.S. sites; NDA submission targeted for Q1 2027.

• Completed Phase 3 trial in early Parkinson's met endpoints in the per-protocol population; open-label extension study is underway.

• Pipeline includes additional indications such as Parkinson's disease dementia, traumatic brain injury, stroke, and combination therapies.

• Over 1,200 individuals have been treated with buntanetap across clinical studies.

Efficacy and safety results

• Buntanetap improved cognition in biomarker-positive mild Alzheimer's patients and showed robust efficacy across subgroups.

• In Parkinson's, the drug improved both motor and cognitive function, with significant benefits in patients with mild dementia and amyloid pathology.

• Biomarker data confirmed reductions in neurotoxic proteins and inflammation in both AD and PD populations.

• Safety profile is strong, with low rates of serious adverse events and consistent tolerability in both APOE4 carriers and non-carriers.

Mechanism of action and scientific rationale

• Buntanetap is a small molecule that targets RNA to inhibit the translation of multiple neurotoxic proteins implicated in neurodegeneration.

• Demonstrated specific binding to APP IRE, reducing synthesis of amyloid, tau, and other proteins.

• Preclinical and clinical data show buntanetap improves axonal transport, reduces inflammation, and protects nerve cells from death.